Holen Sie sich die Stockscreener-App
19.50
12.00%
2.09
Schlusskurs vom Vortag:
$17.41
Offen:
$19.13
24-Stunden-Volumen:
39,684
Relative Volume:
2.51
Marktkapitalisierung:
$6.53B
Einnahmen:
$417.75M
Nettoeinkommen (Verlust:
$32.27M
KGV:
200.00
EPS:
0.0975
Netto-Cashflow:
-
1W Leistung:
+13.44%
1M Leistung:
+15.66%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.01
$20.00
1-Wochen-Bereich:
$16.92
$20.00
52-Wochen-Spanne:
$14.01
$20.00
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Firmenname
Telix Pharmaceuticals Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
19.50 | 6.53B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Eingeleitet | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - GlobeNewswire Inc.
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - StockTitan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - StockTitan
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - StockTitan
Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter - The Pharma Letter
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - GlobeNewswire
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - The Australian Financial Review
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters.com
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Finanzdaten der Telix Pharmaceuticals Ltd Adr-Aktie (TLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):